

Mesenchymal Stem Cell-Derived Exosomes

Subjects: Cell Biology

Contributor: Lihua Dong

Mesenchymal stem cells (MSCs) are multipotent stem cells that can be isolated from human tissues or organs, such as the bone marrow, adipose tissue, umbilical cord, lung, spleen, liver or kidney, while exosomes are crucial components that account for the paracrine action of MSCs. They are extracellular vesicles with a lipid bilayer structure and an average diameter of 100 nm, and they perform biological function by transferring bioactive molecules such as miRNAs, lncRNAs, lipids and cytokines.

Keywords: mesenchymal stem cell ; exosome ; radiation damage

1. Introduction

Mesenchymal stem cells (MSCs) are multipotent stem cells that can be isolated from human tissues or organs, such as the bone marrow, adipose tissue, umbilical cord, lung, spleen, liver or kidney [1]. Despite being derived from multiple sources, MSCs display similar biological phenotypes and functions [2][3]. Because of their autocrine and paracrine actions, MSCs have been shown to possess potency in repairing tissue damage [4]. Critically, delivery of only a small population of MSCs can result in accelerated damage repair in the host [5][6][7]. In addition, exosomes are crucial components that account for the paracrine action of MSCs [8][9][10]. For example, they exchange genetic material across cells by transferring bioactive molecules [11]. Similar to other cellular exosomes, MSC-exosomes are extracellular vesicles with a lipid bilayer structure and an average diameter of 100 nm [1][12]. They carry bioactive molecules, including miRNAs, lncRNAs, lipids and cytokines [1], thus providing a context for researching the biological functions of MSC-exosomes.

Treating diseases with MSC-exosomes has shown promise in the field of regenerative medicine, and numerous studies exploring the therapeutic effects of MSC-exosomes on neurological, immunological and cardiovascular diseases have been published [13]. In summary, the benefits of delivering MSC-exosomes in disease models mainly include the attenuation of inflammation, promotion of angiogenesis and improvement in the survival and proliferation of stem or progenitor cells within injured tissues or organs [14]. In fact, such benefits can be achieved with MSCs as well. Although it has also been shown that MSCs can exert therapeutic effects on radiation damage, the therapeutic potential of MSC-exosomes has not been widely explored in this field. Nevertheless, in a previous study, irradiated cells exhibited enhanced uptake of exosomes because of an increase in the formation of the integrin and tetraspanin complex CD29/CD81 on the cell surface [15], thus indicating the specific role of exosomes in mediating biological processes in injured cells. Moreover, MSC-exosomes were found to protect against acute or chronic radiation damage via their miRNA cargo, suggesting that irradiated cells might utilize MSC-exosomes to increase their resistance to ionizing irradiation [16][17][18]. For example, a study showed that exosomal miRNA-210 could elicit efficient DNA damage repair by controlling the transcriptional activity of HIF-1, thus enhancing cellular radio-resistance [17][19]. In this review, we explore the pro-regenerative properties of MSC-exosomes in the field of radiation damage and aim to provide new insight into the management of radiation damage by using MSC-exosomes.

2. Biological Features of MSC-Exosomes

MSCs are crucial sources of exosomes in humans. Consistent with other cell-derived exosomes, MSC-exosomes are generated through a sequential process including the invagination of lysosomal microparticles and fusion and excretion from parental cells [20]. Lysosomal microparticles first invaginate their membranes to generate endosomes, which then fuse with each other to form multivesicular bodies that contain intraluminal vesicles. Next, the outer membrane of the mature multivesicular body fuses with the plasma membrane of a cell and is ultimately transported out, constituting an exosome [20].

Exosomes consist of lipid bilayer membrane structures with diameters ranging from 40 nm to 160 nm (an average of 100 nm) [12]. They express various markers, including CD9, CD81, CD63, TSG101, flotillin, ceramide, and Alix [12], and have a density of 1.15–1.19 g/mL in sucrose gradients [21]. MSC-exosomes contain at least 170 different miRNAs [22] and 304

proteins [23], along with an indefinite number of DNAs, mRNAs and metabolites [12]. Because they contain a large number of bioactive molecules, MSC-exosomes have attracted great interest in the field of regenerative medicine. Accordingly, numerous studies have attempted to assess whether the infusion of MSC-exosomes can serve as an alternative strategy to repair tissue damage, and emerging results have mostly revealed that MSC-exosomes have therapeutic effects similar to those of their parental MSCs [24]. Moreover, MSC-exosomes have several advantages over MSCs. (i) MSC-exosomes are long-lasting and can be stored at $-80\text{ }^{\circ}\text{C}$ without affecting their biological functions [17], whereas cryopreserved MSCs exhibit impaired immunoregulatory and pro-regenerative properties compared with fresh MSCs [25]. (ii) The membranes of MSC-exosomes are enriched in sphingomyelin, cholesterol, ceramide and lipid raft proteins, enabling MSC-exosomes to spread in vivo regardless of biological barriers, such as the blood-brain barrier [26], for example, even when they are delivered via an intravenous injection, MSC-exosomes can be detected in injured neurons in the brain [27]. (iii) Infusion of MSC-exosomes elicits minimal immune rejection due to their complete lack of expression of major histocompatibility complex (MHC) molecules [28][29], which prevents their rapid clearance by host immune cells. For instance, MSC-exosomes were found to remain in a recipient for a significantly longer time than MSCs after infusion [28][30], indicating that they can perform their biological functions in vivo for a relatively long time. (iv) Infusion of MSC-exosomes can avoid several stem cell-associated challenges, such as the risk of spontaneous tumorigenesis induced by MSCs [31][32]. (v) The potential secretion of exosomes by MSCs can be impacted by various factors. For example, maintaining MSCs in a physiological state in an in vitro culture system can impact their production of exosomes with a specific phenotype in terms of biological activity [33]. Notably, although incubating MSCs with an IFN- γ plus TNF- α mixture in vitro reduced their proliferation, the production of exosomes was not adversely affected [28][34]. Moreover, this process improved the immunosuppressive function of the MSC-exosomes. This prompts speculation that exosomes with high bioactivity can be purposefully obtained by preconditioning MSCs in vitro prior to injection to treat inflammatory diseases. Therefore, determining the components of MSC-exosomes that are able to produce high therapeutic efficacy is particularly critical.

The miRNA and protein cargo contained in MSC-exosomes are effective in promoting damage repair. Moreover, they jointly regulate the regenerative process in damaged tissue. In a colitis model, MSC-exosomes were revealed to reduce macrophage-induced inflammation by transporting metallothionein-2, an upstream protein that blocks activation of the NF- κ B pathway [28]. However, this anti-inflammatory effect of MSC-exosomes was not completely lost even when blocking metallothionein-2 in vivo and in vitro [28], demonstrating that other components in MSC-exosomes also exert bioactive effects in this process. Therefore, exosomal miRNA-146a in MSCs might alleviate experimental colitis by targeting the *TRAF6* and *IRAK1* genes [35], preventing NF- κ B activation along with the subsequent production of TNF- α and IL-6 [35]. Consistently, several other MSC-exosomal miRNAs such as miRNA-30b-3p [36], miRNA-223-3p [37], and miRNA-126 [38][39] were found to be responsible for suppressing pro-inflammatory responses. They also exhibit potent effects in promoting tissue regeneration and angiogenesis. Overall, we need to understand the mechanisms by which MSC-exosomes repair tissue damage.

3. MSC-Exosomes in Repairing Radiation Damage: Perspective and Challenges

With regard to radiation-induced damage, it has been revealed that MSCs play a crucial role in tissue damage treatment and prevention. Moreover, the superior properties and improved safety of MSC-exosomes make them novel candidates for curing radiation-induced damage. They exert therapeutic effects mainly by facilitating angiogenesis, promoting cellular regeneration, and probably by enhancing the repair function through immunomodulatory effects. More importantly, there are several methods that can be used to enhance the efficacy of remodeling damaged tissue. On the one hand, exosomes secreted by MSCs with genetic modifications are a promising alternative treatment, such as exosomes derived from SDF1-overexpressing MSCs for microvascular regeneration [39]. On the other hand, MSCs can be pretreated in vitro before exosomes are collected, such as with hypoxia-treated MSC-exosomes in ischemia-related disease [40]. Last, but equally important, the tropism of exosomes can be improved by increasing expression of specific receptors on the surface of the original MSCs. Current studies on the treatment of radiation-induced damage by MSC-exosomes are mostly based on the acute phase, whereas little work has been performed on the treatment of chronic radiation-induced damage by MSC-exosomes. Notably, evidence suggests that MSC-exosomes reverse EMT of endometrial epithelial cells via the TGF- β 1/Smad pathway [41] and of tubular epithelial cells via enhanced tight junctions [42]. In general, sustained EMT is a critical mechanism that underlies the fibrotic pathology of tissue [43]. Thus, it can be reasonably inferred that MSC-exosome treatment has potential for preventing tissue fibrosis in the chronic phase of tissue damage. Therefore, despite limited evidence of the repair role of MSC-exosomes in chronic radiation-induced damage, it is important that researchers make further efforts to explore their therapeutic and underlying potential in chronic radiation-induced damage. This will provide a new context for the future application of MSC-exosomes to treating chronic radiation damage (Figure 1).

Figure 1. MSC-exosomes are capable of protecting against radiation-induced damage to hematopoietic and nonhematopoietic systems. In hematopoietic reconstruction post irradiation, MSC-exosomes enhance hematopoietic cell survival and proliferation by carrying functional molecules, such as the pro-regeneration miRNAs miRNA221, miRNA451 and miRNA654, the anti-apoptosis-related miRNAs miRNA210, miRNA106b and miRNA155, the hematopoiesis-related cytokines G-CSF and IL-8, and the hematopoiesis-related growth factor VEGF. In addition, MSC-exosomes can protect irradiated bone marrow MSCs from radiation-induced DNA and oxidative stress damage by activating the Wnt/ β -catenin signaling pathway. With regard to the non-hematopoietic system, MSC-exosomes reduce apoptosis of skin epidermal, lung alveolar epithelium and intestinal epithelium cells, as MSC-exosomal miRNAs likely mediate repair of DNA double-strand breaks in damaged cells. Oxidative stress reaction and DNA damage are the major processes in radiation damage. MSC-exosomes can overcome these crucial events effectively, and have potential to suppress the development of acute and chronic radiation damage from several aspects. MSC-exosomes also facilitate vascular endothelium proliferation owing to their bioactive cargo molecules, such as PDGF, FGF and EGF.

In fact, there are several deficiencies with regard to managing diseases by using MSC-exosomes. (i) One concern is the challenges due to the instability of contents of exosomes. For example, studies have shown that the amount of exosomal miRNA cargo is influenced by the irradiation dose and pH value of the culture medium [44][45]. The precise experimental conditions for exosomes are more difficult to control compared to MSCs. (ii) Another concern is the lack of a uniform standard for the purification and quantification of exosomes from conditioned media. Overall, it is difficult to determine the equivalent dose of exosomes in dose-dependent experimental studies, which may lead to different conclusions as results can be affected by exosome content and impurities. Therefore, it is appropriate to find an ideal method for constructing a precise equivalent dose of exosomes for experimental purpose. Although the effects of MSC-exosomes in various disease models have been clearly shown, the exact components and mechanisms of therapy are not entirely clear. miRNAs and functional proteins may play major roles, yet the role of MSC-exosomes in tumor growth and metastasis remains controversial. Previous studies have shown that MSC-exosomes can promote tumor growth in vivo [46], but a recent study revealed that MSC-exosomes enhance radiotherapy-induced tumor cell death in primary and metastatic tumor foci through synergistic and bystander effects [47]. Urgent issues for cancer patients receiving radiotherapy include the adjuvant antitumor effect and resistance to radiation damage. There is a great need for researchers to elaborate on the role of MSC-exosomes in regenerative medicine for the treatment of radiation damage.

References

1. Ruenn Chai Lai; Ronne Wee Yeh Yeo; Sai Kiang Lim; Mesenchymal stem cell exosomes. *Seminars in Cell & Developmental Biology* **2015**, *40*, 82-88, [10.1016/j.semcdb.2015.03.001](https://doi.org/10.1016/j.semcdb.2015.03.001).
2. Danielle Jaqueta Barberini; Natália Pereira Paiva Freitas; Mariana Sartori Magnoni; Leandro Maia; Amanda Jerônimo L. Istoni; Marta Cristina Heckler; Mateus José Sudano; Marjorie Assis Golim; Fernanda Da Cruz Landim-Alvarenga; Rogé

- rio Martins Amorim; et al. Equine mesenchymal stem cells from bone marrow, adipose tissue and umbilical cord: immunophenotypic characterization and differentiation potential. *Stem Cell Research & Therapy* **2014**, *5*, 25-25, [10.1186/scr414](https://doi.org/10.1186/scr414).
3. Marius Strioga; Sowmya Viswanathan; Adas Darinskas; Ondrej Slaby; Jaroslav Michalek; Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells. *Stem Cells and Development* **2012**, *21*, 2724-2752, [10.1089/scd.2011.0722](https://doi.org/10.1089/scd.2011.0722).
 4. Rebekah Margaret Samsonraj; Michael Raghunath; Victor Nurcombe; James H. Hui; Andre J. Van Wijnen; Simon M. Cooley; Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine. *STEM CELLS Translational Medicine* **2017**, *6*, 2173-2185, [10.1002/sctm.17-0129](https://doi.org/10.1002/sctm.17-0129).
 5. Michael Creane; Linda Howard; T. O'Brien; Cynthia M Coleman; Biodistribution and retention of locally administered human mesenchymal stromal cells: Quantitative polymerase chain reaction-based detection of human DNA in murine organs. *Cytotherapy* **2017**, *19*, 384-394, [10.1016/j.jcyt.2016.12.003](https://doi.org/10.1016/j.jcyt.2016.12.003).
 6. Jonathan Ferrand; Danièle Noël; Philippe Lehours; Martina Prochazkova-Carlotti; Lucie Chambonnier; Armelle Ménard; Francis Megraud; Christine Varon; Human Bone Marrow-Derived Stem Cells Acquire Epithelial Characteristics through Fusion with Gastrointestinal Epithelial Cells. *PLOS ONE* **2011**, *6*, e19569, [10.1371/journal.pone.0019569](https://doi.org/10.1371/journal.pone.0019569).
 7. Wujun Geng; Hongli Tang; Shan Luo; Ya Lv; Dongdong Liang; Xianhui Kang; Wandong Hong; Exosomes from miRNA-126-modified ADSCs promotes functional recovery after stroke in rats by improving neurogenesis and suppressing microglia activation. *American journal of translational research* **2019**, *11*, 780-792, .
 8. Thomas J. Morrison; Megan V. Jackson; Erin K. Cunningham; Adrien Kissenpfennig; Daniel F. McAuley; Cecilia M. O'Keefe; Anna D. Krasnodembskaya; Mesenchymal Stromal Cells Modulate Macrophages in Clinically Relevant Lung Injury Models by Extracellular Vesicle Mitochondrial Transfer. *American Journal of Respiratory and Critical Care Medicine* **2017**, *196*, 1275-1286, [10.1164/rccm.201701-0170oc](https://doi.org/10.1164/rccm.201701-0170oc).
 9. Gyeong Joon Moon; Ji Hee Sung; Dong Hee Kim; Eun Hee Kim; Yeon Hee Cho; Jeong Pyo Son; Jae Min Cha; Oh Young Bang; Application of Mesenchymal Stem Cell-Derived Extracellular Vesicles for Stroke: Biodistribution and MicroRNA A Study. *Translational Stroke Research* **2018**, *10*, 509-521, [10.1007/s12975-018-0668-1](https://doi.org/10.1007/s12975-018-0668-1).
 10. Mathilde Mathieu; Lorena Martín-Jaular; Grégory Lavie; Clotilde Théry; Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. *Nature* **2019**, *21*, 9-17, [10.1038/s41556-018-0250-9](https://doi.org/10.1038/s41556-018-0250-9).
 11. Hadi Valadi; Karin Ekström; Apostolos Bossios; Margareta Sjöstrand; James J Lee; Jan O L Ouml Tvall; Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nature* **2007**, *9*, 654-659, [10.1038/ncb1596](https://doi.org/10.1038/ncb1596).
 12. Raghu Kalluri; Valerie S. LeBleu; The biology, function, and biomedical applications of exosomes. *Science* **2020**, *367*, eaa6977, [10.1126/science.aa6977](https://doi.org/10.1126/science.aa6977).
 13. Fanny M. Elahi; D. Gregory Farwell; Jan A. Nolte; Johnathon D. Anderson; Preclinical translation of exosomes derived from mesenchymal stem/stromal cells. *STEM CELLS* **2019**, *38*, 15-21, [10.1002/stem.3061](https://doi.org/10.1002/stem.3061).
 14. Milad Riazifar; M. Rezaa Mohammadi; Egest J. Pone; Ashish Yeri; Cecilia Lässer; Aude I. Ségaliny; Laura L. McIntyre; Ganesh Vilas Shelke; Elizabeth Hutchins; Ashley Hamamoto; et al. Stem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders. *ACS Nano* **2019**, *13*, 6670-6688, [10.1021/acsnano.9b01004](https://doi.org/10.1021/acsnano.9b01004).
 15. Masaharu Hazawa; Kenichi Tomiyama; Ai Saotome-Nakamura; Chizuka Obara; Takeshi Yasuda; Takaya Gotoh; Izumi Tanaka; Haruko Yakumaru; Hiroshi Ishihara; Katsushi Tajima; et al. Radiation increases the cellular uptake of exosomes through CD29/CD81 complex formation. *Biochemical and Biophysical Research Communications* **2014**, *446*, 1165-1171, [10.1016/j.bbrc.2014.03.067](https://doi.org/10.1016/j.bbrc.2014.03.067).
 16. Lena Pinzur; Levent Akyuez; Lilia Levdansky; Michal Blumenfeld; Evgenia Volinsky; Zami Aberman; Petra Reinke; Rachel Ofir; Hans-Dieter Volk; Raphael Gorodetsky; et al. Rescue from lethal acute radiation syndrome (ARS) with severe weight loss by secretome of intramuscularly injected human placental stromal cells. *Journal of Cachexia, Sarcopenia and Muscle* **2018**, *9*, 1079-1092, [10.1002/jcsm.12342](https://doi.org/10.1002/jcsm.12342).
 17. Sicheng Wen; Mark Dooner; Yan Cheng; Elaine Papa; Michael Del Tatto; Mandy Pereira; Yanhui Deng; Laura Goldberg; Jason Aliotta; Devasis Chatterjee; et al. Mesenchymal stromal cell-derived extracellular vesicles rescue radiation damage to murine marrow hematopoietic cells. *Leukemia* **2016**, *30*, 2221-2231, [10.1038/leu.2016.107](https://doi.org/10.1038/leu.2016.107).
 18. John A. Kink; Matthew H. Forsberg; Sofiya Reshetylo; Soroush Besharat; Charlie J. Childs; Jessica D. Pederson; Annette Gendron-Fitzpatrick; Melissa Graham; Paul D. Bates; Eric G. Schmuck; et al. Macrophages Educated with Exosomes from Primed Mesenchymal Stem Cells Treat Acute Radiation Syndrome by Promoting Hematopoietic Recovery. *Biology of Blood and Marrow Transplantation* **2019**, *25*, 2124-2133, [10.1016/j.bbmt.2019.07.026](https://doi.org/10.1016/j.bbmt.2019.07.026).

19. S Grosso; J Doyen; S K Parks; T Bertero; A Paye; B Cardinaud; P Gounon; S Lacas-Gervais; A Noël; J Pouysségur; et al. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. *Cell Death & Disease* **2013**, *4*, e544-e544, [10.1038/cddis.2013.71](https://doi.org/10.1038/cddis.2013.71).
20. Chuanjiang He; Shu Zheng; Yan Luo; Ben Wang; Exosome Theranostics: Biology and Translational Medicine. *Theranostics* **2018**, *8*, 237-255, [10.7150/thno.21945](https://doi.org/10.7150/thno.21945).
21. Clotilde Théry; Sebastian Amigorena; Graça Raposo; Aled Clayton; Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids. *Current Protocols in Cell Biology* **2006**, *30*, 3.22.1-3.22.29, [10.1002/0471143030.cb0322s30](https://doi.org/10.1002/0471143030.cb0322s30).
22. Scott W. Ferguson; Jinli Wang; Christine J. Lee; Maixian Liu; Sriram Neelamegham; John M. Canty; Juliane Nguyen; The microRNA regulatory landscape of MSC-derived exosomes: a systems view. *Scientific Reports* **2018**, *8*, 1419, [10.1038/s41598-018-19581-x](https://doi.org/10.1038/s41598-018-19581-x).
23. Chengfeng Xun; Lite Ge; Feng Tang; Lu Wang; Yi Zhuo; Lang Long; Jiaomei Qi; Li Hu; Da Duan; Ping Chen; et al. Insight into the proteomic profiling of exosomes secreted by human OM-MSCs reveals a new potential therapy. *Biomedicine & Pharmacotherapy* **2020**, *131*, 110584, [10.1016/j.biopha.2020.110584](https://doi.org/10.1016/j.biopha.2020.110584).
24. Lianbo Shao; Yu Zhang; Beibei Lan; Juanjuan Wang; Zhiwei Zhang; Lulu Zhang; Pengli Xiao; Qingyou Meng; Yong-Jian Geng; Xi-Yong Yu; et al. MiRNA-Sequence Indicates That Mesenchymal Stem Cells and Exosomes Have Similar Mechanism to Enhance Cardiac Repair. *BioMed Research International* **2017**, *2017*, 1-9, [10.1155/2017/4150705](https://doi.org/10.1155/2017/4150705).
25. Guido Moll; Jessica J. Alm; Lindsay C. Davies; Lena Von Bahr; Nina Heldring; Lillemor Stenbeck-Funke; Osama A. Hamad; Robin Hinsch; Lech Ignatowicz; Matthew Locke; et al. Do Cryopreserved Mesenchymal Stromal Cells Display Impaired Immunomodulatory and Therapeutic Properties?. *STEM CELLS* **2014**, *32*, 2430-2442, [10.1002/stem.1729](https://doi.org/10.1002/stem.1729).
26. Soon Sim Tan; Yijun Yin; Tricia Lee; Ruenn Chai Lai; Ronne Wee Yeh Yeo; Bin Zhang; Andre Choo; Sai Kiang Lim; The therapeutic MSC exosomes are derived from lipid raft microdomains in the plasma membrane. *Journal of Extracellular Vesicles* **2013**, *2*, 1, [10.3402/jev.v2i0.22614](https://doi.org/10.3402/jev.v2i0.22614).
27. Lydia Alvarez-Erviti; Yiqi Seow; Haifang Yin; Corinne Betts; Samira Lakhal; Matthew J A Wood; Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nature Biotechnology* **2011**, *29*, 341-345, [10.1038/nbt.1807](https://doi.org/10.1038/nbt.1807).
28. Huashan Liu; Zhenxing Liang; Fengwei Wang; Chi Zhou; Xiaobin Zheng; Tuo Hu; Xiaowen He; Xianrui Wu; Ping Lan; Exosomes from mesenchymal stromal cells reduce murine colonic inflammation via a macrophage-dependent mechanism. *JCI Insight* **2019**, *4*, 4, [10.1172/jci.insight.131273](https://doi.org/10.1172/jci.insight.131273).
29. Jose Marino; Joshua Paster; Gilles Benichou; Allorecognition by T Lymphocytes and Allograft Rejection. *Frontiers in Immunology* **2016**, *7*, 582, [10.3389/fimmu.2016.00582](https://doi.org/10.3389/fimmu.2016.00582).
30. E Gonzalez-Rey; P Anderson; M A Gonzalez; L Rico; D Buscher; M Delgado; Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. *Gut* **2009**, *58*, 929-939, [10.1136/gut.2008.168534](https://doi.org/10.1136/gut.2008.168534).
31. Vladislav Volarevic; Bojana Simovic Markovic; Marina Gazdic; Ana Volarevic; Nemanja Jovicic; Nebojsa Arsenijevic; Lyle Armstrong; Valentin Djonov; Majlinda Lako; Miodrag Stojkovic; et al. Ethical and Safety Issues of Stem Cell-Based Therapy. *International Journal of Medical Sciences* **2018**, *15*, 36-45, [10.7150/ijms.21666](https://doi.org/10.7150/ijms.21666).
32. Gro Vatne Røslund; Agnete Svendsen; Anja Torsvik; Ewa Sobala; Emmet McCormack; Heike Immervoll; Josef Mysliwiec; J. C. Tonn; Roland Goldbrunner; Per Eystein Lønning; et al. Long-term Cultures of Bone Marrow-Derived Human Mesenchymal Stem Cells Frequently Undergo Spontaneous Malignant Transformation. *Cancer Research* **2009**, *69*, 5331-5339, [10.1158/0008-5472.can-08-4630](https://doi.org/10.1158/0008-5472.can-08-4630).
33. Daniela Hladik; Ines Höfig; Ursula Oestreicher; Johannes Beckers; Martina Matjanovski; Xuanwen Bao; Harry Scherthan; Michael J. Atkinson; Michael Rosemann; Long-term culture of mesenchymal stem cells impairs ATM-dependent recognition of DNA breaks and increases genetic instability. *Stem Cell Research & Therapy* **2019**, *10*, 1-12, [10.1186/s13287-019-1334-6](https://doi.org/10.1186/s13287-019-1334-6).
34. Rossana Domenis; Adriana Cifù; Sara Quaglia; Cinzia Pistis; Massimo Moretti; Annalisa Vicario; Pier Camillo Parodi; Martina Fabris; Kayvan R. Niazi; Patrick Soon-Shiong; et al. Pro-inflammatory stimuli enhance the immunosuppressive functions of adipose mesenchymal stem cells-derived exosomes. *Scientific Reports* **2018**, *8*, 1-11, [10.1038/s41598-018-31707-9](https://doi.org/10.1038/s41598-018-31707-9).
35. Hui Wu; Heng Fan; Zhexing Shou; Meng Xu; Qianyun Chen; Changzheng Ai; Yalan Dong; Yujin Liu; Zhen Nan; Yifan Wang; et al. Extracellular vesicles containing miR-146a attenuate experimental colitis by targeting TRAF6 and IRAK1. *International Immunopharmacology* **2019**, *68*, 204-212, [10.1016/j.intimp.2018.12.043](https://doi.org/10.1016/j.intimp.2018.12.043).
36. Xiaomeng Yi; Xuxia Wei; Haijin Lv; Yuling An; Lijuan Li; Pinglan Lu; Yang Yang; Qi Zhang; Huimin Yi; Guihua Chen; et al. Exosomes derived from microRNA-30b-3p-overexpressing mesenchymal stem cells protect against lipopolysaccharide-induced acute lung injury by inhibiting SAA3. *Experimental Cell Research* **2019**, *383*, 111454, [10.1016/j.yexcr.2019.05.035](https://doi.org/10.1016/j.yexcr.2019.05.035).

37. Feng-Bin Lu; Da-Zhi Chen; Lu Chen; En-De Hu; Jin-Lu Wu; Hui Li; Yüewen Gong; Zhuo Lin; Xiao-Dong Wang; Ji Li; et al. Attenuation of Experimental Autoimmune Hepatitis in Mice with Bone Mesenchymal Stem Cell-Derived Exosomes Carrying MicroRNA-223-3p.. *null* **2019**, *42*, 906-918, .
38. Wei Liu; Linwei Li; Yuluo Rong; Dingfei Qian; Jian Chen; Zheng Zhou; Yongjun Luo; Dongdong Jiang; Lin Cheng; Shujie Zhao; et al. Hypoxic mesenchymal stem cell-derived exosomes promote bone fracture healing by the transfer of miR-126. *Acta Biomaterialia* **2020**, *103*, 196-212, [10.1016/j.actbio.2019.12.020](https://doi.org/10.1016/j.actbio.2019.12.020).
39. Wei Du; Kaiyue Zhang; Shuaiqiang Zhang; Ran Wang; Yan Nie; Hongyan Tao; Zhibo Han; Lu Liang; Di Wang; Jianfeng Liu; et al. Enhanced proangiogenic potential of mesenchymal stem cell-derived exosomes stimulated by a nitric oxide releasing polymer. *Biomaterials* **2017**, *133*, 70-81, [10.1016/j.biomaterials.2017.04.030](https://doi.org/10.1016/j.biomaterials.2017.04.030).
40. Tatiana Lopatina; Stefania Bruno; Ciro Tetta; Natalia Kalinina; Massimo Porta; Giovanni Camussi; Platelet-derived growth factor regulates the secretion of extracellular vesicles by adipose mesenchymal stem cells and enhances their angiogenic potential. *Cell Communication and Signaling* **2014**, *12*, 26-26, [10.1186/1478-811x-12-26](https://doi.org/10.1186/1478-811x-12-26).
41. Yuan Yao; Ran Chen; Guowu Wang; Yu Zhang; Fang Liu; Exosomes derived from mesenchymal stem cells reverse EMT via TGF- β 1/Smad pathway and promote repair of damaged endometrium. *Stem Cell Research & Therapy* **2019**, *10*, 1-17, [10.1186/s13287-019-1332-8](https://doi.org/10.1186/s13287-019-1332-8).
42. Kanna Nagaishi; Yuka Mizue; Takako Chikenji; Miho Otani; Masako Nakano; Naoto Konari; Mineko Fujimiya; Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes. *Scientific Reports* **2016**, *6*, 34842, [10.1038/srep34842](https://doi.org/10.1038/srep34842).
43. Rivka C. Stone; Irena Pastar; Nkemcho Ojeh; Vivien Chen; Sophia Liu; Karen I. Garzon; Marjana Tomic-Canic; Epithelial-mesenchymal transition in tissue repair and fibrosis. *Cell and Tissue Research* **2016**, *365*, 495-506, [10.1007/s00441-016-2464-0](https://doi.org/10.1007/s00441-016-2464-0).
44. Agata Abramowicz; Wojciech Łabaj; Justyna Mika; Katarzyna Szoltysek; Izabella Ślęzak-Prochazka; Łukasz Mielańczyk; Michael D. Story; Monika Pietrowska; Andrzej Polański; Piotr Widłak; et al. MicroRNA Profile of Exosomes and Parental Cells is Differently Affected by Ionizing Radiation. *Radiation Research* **2020**, *194*, 133, [10.1667/rade-20-00007](https://doi.org/10.1667/rade-20-00007).
45. Anjana Jeyaram; Tek N. Lamichhane; Sheng Wang; Lin Zou; Eshan Dahal; Stephanie M. Kronstadt; Daniel Levy; Babita Parajuli; Daphne R. Knudsen; Wei Chao; et al. Enhanced Loading of Functional miRNA Cargo via pH Gradient Modification of Extracellular Vesicles. *Molecular Therapy* **2020**, *28*, 975-985, [10.1016/j.ymthe.2019.12.007](https://doi.org/10.1016/j.ymthe.2019.12.007).
46. Wei Zhu; Ling Huang; Yahong Li; Xu Zhang; Jianmei Gu; Yongmin Yan; Xiaomeng Xu; Mei Wang; Hui Qian; Wenrong Xu; et al. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. *Cancer Letters* **2012**, *315*, 28-37, [10.1016/j.canlet.2011.10.002](https://doi.org/10.1016/j.canlet.2011.10.002).
47. Virgínea De Araujo Farias; F. O' Valle; Santiago Serrano-Saenz; Per Anderson; Eduardo Andrés-León; Jesús J. López-Peñalver; Isabel Tovar; Ana Nieto; Ana Santos; Francisco Martín; et al. Exosomes derived from mesenchymal stem cells enhance radiotherapy-induced cell death in tumor and metastatic tumor foci. *Molecular Cancer* **2018**, *17*, 1-12, [10.1186/s12943-018-0867-0](https://doi.org/10.1186/s12943-018-0867-0).

Retrieved from <https://encyclopedia.pub/entry/history/show/16116>